Dashtipour, Khashayar
Wietek, Stefan
Rubin, Bruce
Maisonobe, Pascal
Bahroo, Laxman
Trosch, Richard
Funding for this research was provided by:
Ipsen Biopharmaceuticals (Not applicable)
Article History
Received: 29 April 2020
Accepted: 10 August 2020
First Online: 31 August 2020
Ethics approval and consent to participate
: This study obtained appropriate institutional review board approval and was conducted under the provisions of the Declaration of Helsinki. Patients provided informed consent prior to their enrollment. This study was registered with ClinicalTrials.gov (identifier: NCT01753336).
: Not applicable.
: KD: <i>Advisor/consultant, and/or speaker:</i> Abbvie, ACADIA, Acorda, Adamas, Allergan, Amneal, Impax, Ipsen, Lundbeck, Neurocrine, Revance, Sunovion, Teva, US WorldMeds; SW: <i>Employment:</i> Ipsen; BR: <i>Employment (former):</i> Ipsen; PM: <i>Employment:</i> Ipsen; LB: <i>Speaker’s bureaus:</i> Allergan, Ipsen, Us WorldMeds; <i>Consultant:</i> US WorldMeds; RT:<i> Speaker and/or</i><i>Consultant:</i> Ipsen, Neurocrine, Acadia, Amneal, and US WorldMeds.